Colom Matthieu, Vidal Benjamin, Fieux Sylvain, Redoute Jérôme, Costes Nicolas, Lavenne Franck, Mérida Inés, Irace Zacharie, Iecker Thibaud, Bouillot Caroline, Billard Thierry, Newman-Tancredi Adrian, Zimmer Luc
Lyon Neuroscience Research Center, INSERM, CNRS, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Hospices Civils de Lyon, Lyon, France.
Front Neurosci. 2021 Mar 8;15:622423. doi: 10.3389/fnins.2021.622423. eCollection 2021.
Serotonin is involved in a variety of physiological functions and brain disorders. In this context, efforts have been made to investigate the fluctuations of this neurotransmitter using positron emission tomography (PET) imaging paradigms. Since serotonin is a full agonist, it binds preferentially to G-protein coupled receptors. In contrast, antagonist PET ligands additionally interact with uncoupled receptors. This could explain the lack of sensitivity to serotonin fluctuations of current 5-HT radiopharmaceuticals which are mainly antagonists and suggests that agonist radiotracers would be more appropriate to measure changes in neurotransmitter release. The present study evaluated the sensitivity to endogenous serotonin release of a recently developed, selective 5-HT receptor PET radiopharmaceutical, the agonist [F]F13640 (a.k.a. befiradol or NLX-112).
Four cats each underwent three PET scans with [F]F13640, i.e., a control PET scan of 90 min, a PET scan preceded 30 min before by an intravenous injection 1 mg/kg of d-fenfluramine, a serotonin releaser (blocking challenge), and a PET scan comprising the intravenous injection of 1 mg/kg of d-fenfluramine 30 min after the radiotracer injection (displacement challenge). Data were analyzed with regions of interest and voxel-based approaches. A lp-ntPET model approach was implemented to determine the dynamic of serotonin release during the challenge study.
D-fenfluramine pretreatment elicited a massive inhibition of [F]F13640 labeling in regions known to express 5-HT receptors, e.g., raphe nuclei, hippocampus, thalamus, anterior cingulate cortex, caudate putamen, occipital, frontal and parietal cortices, and gray matter of cerebellum. Administration of d-fenfluramine during PET acquisition indicates changes in occupancy from 10% (thalamus) to 31% (gray matter of cerebellum) even though the dissociation rate of [F]F13640 over the 90 min acquisition time was modest. The lp-ntPET simulation succeeded in differentiating the control and challenge conditions.
The present findings demonstrate that labeling of 5-HT receptors with [F]F13640 is sensitive to serotonin concentration fluctuations . Although the data underline the need to perform longer PET scan to ensure accurate measure of displacement, they support clinical development of [F]F13640 as a tool to explore experimental paradigms involving physiological or pathological (neurological or neuropsychiatric pathologies) fluctuations of extracellular serotonin.
血清素参与多种生理功能和脑部疾病。在此背景下,人们已努力使用正电子发射断层扫描(PET)成像范式来研究这种神经递质的波动。由于血清素是一种完全激动剂,它优先与G蛋白偶联受体结合。相比之下,拮抗剂PET配体还会与未偶联的受体相互作用。这可以解释当前主要为拮抗剂的5-HT放射性药物对血清素波动缺乏敏感性的原因,并表明激动剂放射性示踪剂更适合测量神经递质释放的变化。本研究评估了一种新开发的选择性5-HT受体PET放射性药物,即激动剂[F]F13640(又名贝非拉朵或NLX-112)对内源性血清素释放的敏感性。
四只猫分别接受了三次使用[F]F13640的PET扫描,即一次90分钟的对照PET扫描、一次在静脉注射1mg/kg右芬氟拉明(一种血清素释放剂,阻断激发)30分钟前进行的PET扫描,以及一次在放射性示踪剂注射后30分钟静脉注射1mg/kg右芬氟拉明的PET扫描(置换激发)。数据采用感兴趣区域和基于体素的方法进行分析。采用lp-ntPET模型方法来确定激发研究期间血清素释放的动态变化。
右芬氟拉明预处理在已知表达5-HT受体的区域,如中缝核、海马体、丘脑、前扣带回皮质、尾状壳核、枕叶、额叶和顶叶皮质以及小脑灰质,引发了[F]F13640标记的大量抑制。在PET采集期间给予右芬氟拉明表明占有率从10%(丘脑)变化到31%(小脑灰质),尽管在90分钟采集时间内[F]F13640的解离速率适中。lp-ntPET模拟成功区分了对照和激发条件。
目前的研究结果表明,用[F]F13640标记5-HT受体对血清素浓度波动敏感。尽管数据强调需要进行更长时间的PET扫描以确保准确测量置换,但它们支持将[F]F13640作为一种工具用于探索涉及细胞外血清素生理或病理(神经或神经精神疾病)波动的实验范式的临床开发。